影响血管紧张素II 作用和合成的新途径及研究进展

中国临床药理学与治疗学 ›› 2005, Vol. 10 ›› Issue (7): 726-729.

影响血管紧张素II 作用和合成的新途径及研究进展

张楠综述, 康毅, 娄建石审校

天津医科大学基础医学院药理教研室, 天津300070

收稿日期:2005-04-01 修回日期:2005-06-02 出版日期:2005-07-26 发布日期:2020-11-10
通讯作者: 娄建石, 男, 教授, 博士生导师, 研究方向:心血管药理学与临床药理学。Tel:022-23542686 E-mail: jianshilou@sina.com
作者简介:张楠, 男, 硕士研究生, 研究方向:心血管药理学与临床药理学。Tel:022-23542523 E-mail: garyw6309@eyou.com

New approach to action and biosynthesis of AngII and on it research

ZHANG Nan, KANG Yi, LOU Jian-shi

Department of Pharmacology, Basic Medical College, Tianjin Medical University, Tianjin 300070, China

Received:2005-04-01 Revised:2005-06-02 Online:2005-07-26 Published:2020-11-10

摘要/Abstract

摘要： 肾素-血管紧张素系统(RAS) 与多种疾病相关。作为RAS 的最终效应途径, 血管紧张素II 起到了关键作用。本文综述了能够影响其合成及作用的主要途径:血管紧张素II 受体拮抗剂(ARB) 、糜酶(chymase) 抑制剂和晚近发现的ACE2 类物质及其相关研究。

关键词: 血管紧张素II, ACEI, ACE2, ARB, 糜酶

Abstract: Renin-angiotensin system (RAS) is correlative with many diseases. Angio tensin II (AngII) plays an important role as the final effective approach for RAS. This article reviews the main approach to the action and biosynthesis of AngII: including AngII receptor blocker (ARB), chymase inhibitor and ACE2 which were disscoverd recently.

Key words: AngII, ACEI, ACE2, ARB, chymase

中图分类号:

R972

张楠, 康毅, 娄建石. 影响血管紧张素II 作用和合成的新途径及研究进展[J]. 中国临床药理学与治疗学, 2005, 10(7): 726-729.

ZHANG Nan, KANG Yi, LOU Jian-shi. New approach to action and biosynthesis of AngII and on it research[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(7): 726-729.

参考文献

1 Shuji A. Role of angiotensin II and endogenous vasodilators in the control of glomerular hemodynamics[J]. Clin Exp Nephrol, 2003;7:172-8
2 William FK, Kiyoshi K, Paulette AL, Shahnaz S, Thomas PS, Kenneth KW, et al.Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists:lessons from recent trials[J]. Clin Exp Nephrol, 2002;6:175-81
3 Satoru M, Tsutomu H, Taro S, Kenta O, Reiko I, Mitsuru A. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure[J]. Hypertens Res, 2003; 26:453-8
4 Yasuhiko I, Matsuhiko H, Tetsuya K, Tatsuo S, Yasuhiko T, Kenichi Y, et al.Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the japanese losartan therapy intended for global renal protection in hypertensive patients (jlight) study[J]. Clin Exp Nephrol, 2003; 7:221-30
5 Yasuaki D, Masuo O, Masaya S, Hiroyuki T, Koichi S, Ryuzo U.Candesartan reduces oxidative stress and inflammation in patients with essential hypertension[J]. Hypertens Res, 2003; 26:691-7
6 Lajemi M, Labat C, Gautier S, Lacolley P, Safar M, Asmar R, et al.Angiotensin II type 1 receptor-153 A G and 1166 A C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects[J]. J Hypertens, 2001; 9:407-13
7 Anan F, Takahashi N, Ooie T, Hara M, Yoshimatsu H, Saikawa T.Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance[J]. Metabolism, 2004;53:777-81
8 Yoshida O, Hirayama H, Nanasato M, Watanabe T, Murohara T.The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation:a prospective randomized study under intravascular ultrasound guidance[J]. Am Heart J, 2005; 149:2
9 Roberto F, Amedeo M, Annalisa Z, GianluigiM, Carlo P, Luigi P, et al.Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension[J]. Eur J Clin Pharmacol, 2004; 59:863-8
10 Nagisa YA, Shintani SN.The angiotensin II receptor antagonistcandesartan cilexetil (TCV-116) ameliorates retinal disorders in rats[J]. Diabetologia, 2001; 44:883-8
11 Caiying G, Haisong J, Debbie L, HamidM, Mingda SMR. A novel vascular smooth muscle chymase is upregulated in hypertensive rats[J]. J Clin Invest, 2001;107: 703-15
12 Doggrell SA, Wanstall JC.Vascular chymase: pathophysiological role and therapeutic potential of inhibition[J]. Cardiovasc Res, 2004; 61:653-62
13 Mizuo M, Shinji T.Local angiotensin II-generating system in vascular tissues: the roles of chymase[J]. Hypertens Res, 2001; 24:189-93
14 Shiota N, Okunishi H, Takai S, Mikoshiba I, Sakonjo H, Shibata N, et al.Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery[J]. Circulation, 1999;99: 1084-90
15 Nishimoto M, Takai S, Kim S, Jin D, Yuda A, SakaguchiM, et al.Singigicance of chymase dependent angiotensin II -forming pathway in vascular proliferation[J]. J Hypertens, 2000; 18:S90
16 Li P, Chen PM, Wang SW, Chen LY.Time-dependent expression of chymase and angiotensin converting enzyme in the hamster heart under pressure overload[J]. Hypertens Res, 2002; 25:757-62
17 Hirobumi T, Koichi H, Hiroto M, Eiji K, Masanori H, Ken O, et al.Differential regulation of elevated renal angiotensin II in chronic renal ischemia[J]. Hypertension, 2002;40: 34
18 Morikawa T, Imanishi M, Suzuki H, Okada N, Okumura M, Konishi Y, et al.Mast cell chymase in the ischemic kidney of severe unilateral renovascular hypertension[J]. Am J Kidney Dis, 2005; 45:45-50
19 Huang XR, Chen WY, Truong LD.Chymase is up-regulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease[J]. J Am Soc Nephrol, 2003;14:1738-47
20 McPherson EA, Luo Z, Brown RA, LeBard LS, Corless CC, Speth RC, et al.Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease[J]. J Am Soc Nephrol, 2004; 15:493-500
21 Huang LL, Daniel JS, Kirsten S, Mary D, Rodger S, Indra S, et al.Novel peptide inhibitors of angiotensin-converting enzyme 2[J]. J Biol Chem, 2003;278: 15532-40
22 Lely AT, Hamming I, van Goor H, Navis GJ.Renal ACE2 expression in human kidney disease[J]. J Pathol, 2004; 204:587-93
23 Burrell LM, Johnston CI, Tikellis C, Cooper ME.ACE2, a new regulator of the renin-angiotensin system[J]. Trends Endocrinol Metab, 2004;15:166-9
24 Kuhn JH, Li W, Choe H, Farzan M.Angiotensin-converting enzyme 2:a functional receptor for SARS coronavirus[J]. Cell Mol Life Sci, 2004;61: 2738-43

[1]	彭娟, 范琳琳, 李然宜, 李晓宇, 吕迁洲, 邹云增. 心力衰竭药物治疗的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 373-381.
[2]	占珠琴, 白海涛. 不同剂量地塞米松对脓毒症肾损伤大鼠血管紧张素II及其受体、NO水平变化的影响[J]. 中国临床药理学与治疗学, 2021, 26(9): 995-1004.
[3]	杨贺淳, 史道华 . 调控肿瘤糖代谢重编程改善肿瘤耐药的小分子抑制剂研究进展[J]. 中国临床药理学与治疗学, 2021, 26(7): 836-840.
[4]	李天翔, 李素娟, 郝祥宇, 祝志波, 郭建强. 替米沙坦在动脉粥样硬化中对肠道菌群及其代谢产物TMAO的影响[J]. 中国临床药理学与治疗学, 2020, 25(11): 1233-1241.
[5]	赵巧素，叶桦，孙勤学. 生物钟基因Period2调节肝癌细胞warburg效应及转移侵袭中的作用机制[J]. 中国临床药理学与治疗学, 2019, 24(10): 1134-1141.
[6]	王瑾，杨毅，郭丽，李文燕，阮水良. 普罗布考通过调节肝癌细胞HepG2代谢重编程逆转Warburg效应抑制其转移和侵袭的机制研究[J]. 中国临床药理学与治疗学, 2018, 23(6): 601-607.
[7]	孟晶茜，赵瑛瑛，张文吉，张宛哲，申鹏霄，刘丁，苏晨皓，沈杰，王建生. ACE2基因多态性对厄贝沙坦治疗2级高血压伴慢性肾衰患者疗效的影响[J]. 中国临床药理学与治疗学, 2018, 23(6): 661-666.
[8]	胡坤媚，胡浩然，沈媛媛，卢毅宁，杨解人，韩军. 中药玉夏胶囊对自发性高血压大鼠肾纤维化的改善作用及TGF-β₁ /Smads信号通路的影响[J]. 中国临床药理学与治疗学, 2017, 22(4): 387-393.
[9]	张晓一，于潇华，刘玉环，杨丽，王珍，阳芳，秦旭平，曾泗宇. ERK1/2和p38MAPK在介导CGRP和Ang II诱导血管平滑肌细胞Nox1表达中的作用[J]. 中国临床药理学与治疗学, 2017, 22(1): 13-19.
[10]	郝伟，沈媛媛，张俊秀，杨解人. 玉夏胶囊对自发性高血压大鼠心肌纤维化的影响[J]. 中国临床药理学与治疗学, 2016, 21(4): 378-383.
[11]	俞子恒，韦凡平，程震锋. 小剂量秋水仙碱对不稳定心绞痛合并高尿酸患者胸痛改善的作用[J]. 中国临床药理学与治疗学, 2016, 21(4): 455-457.
[12]	孟云辉, 吴艳霞, 凃欣, 凃晋文. 镇肝熄风汤对自发性高血压大鼠血管紧张素 II 、内皮素的影响[J]. 中国临床药理学与治疗学, 2006, 11(5): 550-553.
[13]	杨柳, 刘昌慧, 王毅, 白玉鹏. 血管紧张素受体阻滞剂对自发性高血压大鼠肾脏血管紧张素转换酶2表达的影响[J]. 中国临床药理学与治疗学, 2005, 10(6): 682-686.
[14]	邹军, 王虹, 冯丹. 血管紧张素-(1-7) 对血管紧张素II致人脐静脉内皮细胞损伤的保护作用研究[J]. 中国临床药理学与治疗学, 2005, 10(2): 180-183.
[15]	林泽鹏, 张治伟, 赵有生, 秦迁, 方卫华. 厄贝沙坦长期治疗对原发性高血压患者左室肥厚及心功能的影响[J]. 中国临床药理学与治疗学, 2005, 10(2): 219-221.